or Try an Advanced Search...

    Technical Analysis for GRTS - Gritstone Oncology, Inc.

    Grade Last Price % Change Price Change
    F 0.03 -31.78% -0.02
    GRTS closed down 31.78 percent on Monday, October 21, 2024, on 2.65 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GRTS trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -31.78%
    Calm After Storm Range Contraction -31.78%
    NR7 Range Contraction -31.78%
    Older End-of-Day Signals for GRTS ...

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GRTS Chart by TradingView
    Basic chart:

    Profile

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell

    Is GRTS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 7 Gritstone bio (GRTSQ) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
    Oct 17 Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Oct 16 Bankrupt Gritstone bio in funding talks
    Oct 11 Gritstone Oncology Pursues Restructuring Through Chapter 11
    Oct 10 Gritstone bio files for Chapter 11 bankruptcy protection, shares tumble
    Oct 10 Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
    Oct 2 Gritstone downgraded by Jones, B. Riley over cancer vaccine data
    Oct 1 Gritstone stock craters 50% in wake of Phase 2 data, corporate update
    Sep 30 Gritstone falls amid Phase 2 Granite data, corporate update
    Sep 30 Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
    See more GRTS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.17
    52 Week Low 0.031
    Average Volume 21,017,655
    200-Day Moving Average 1.17
    50-Day Moving Average 0.40
    20-Day Moving Average 0.24
    10-Day Moving Average 0.08
    Average True Range 0.04
    RSI (14) 18.70
    ADX 42.17
    +DI 14.78
    -DI 48.63
    Chandelier Exit (Long, 3 ATRs) 0.53
    Chandelier Exit (Short, 3 ATRs) 0.16
    Upper Bollinger Bands 0.67
    Lower Bollinger Band -0.19
    Percent B (%b) 0.26
    BandWidth 357.60
    MACD Line -0.12
    MACD Signal Line -0.11
    MACD Histogram -0.0126
    Fundamentals Value
    Market Cap 3.07 Million
    Num Shares 95.3 Million
    EPS -1.24
    Price-to-Earnings (P/E) Ratio -0.03
    Price-to-Sales 20.98
    Price-to-Book 2.90
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.05
    Resistance 3 (R3) 0.05 0.04 0.04
    Resistance 2 (R2) 0.04 0.04 0.04 0.04
    Resistance 1 (R1) 0.04 0.04 0.04 0.04 0.04
    Pivot Point 0.03 0.03 0.03 0.03 0.03
    Support 1 (S1) 0.03 0.03 0.03 0.03 0.02
    Support 2 (S2) 0.03 0.03 0.02 0.02
    Support 3 (S3) 0.02 0.03 0.02
    Support 4 (S4) 0.02